Compare ACADIA Pharmaceuticals Inc. (ACAD) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while YieldMax Universe Fund of Option Income ETFs trades at $7.84. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| ACAD | YMAX | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $28.06 | $14.00 |
52-Week Low | $20.06 | $7.51 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
YMAX trades at $8.09, up 2.15% with a bearish technical signal from moving averages. The ETF generates high income through weekly distributions, though recent analysis suggests distributions include significant return of capital. Technical indicators show mixed signals with RSI at 73.39 suggesting overbought conditions while ADX indicates weakening trend strength.
YMAX offers high yield potential but faces challenges from its complex options strategy and expense structure. The fund's 1.33% total expense ratio and dependence on market volatility create headwinds for long-term capital appreciation. Investors should weigh the high income against potential NAV erosion from return of capital distributions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
